Digital health is the broadest umbrella in the field — the FDA uses it to cover essentially any technology that touches health: mobile health (mHealth) apps, health information technology, wearables, telehealth and telemedicine, and personalized medicine. Because it is so wide, the term itself is descriptive rather than legal. Calling a product "digital health" creates no obligations on its own; it is a category, not a trigger.
What actually creates obligations are three concrete questions hiding underneath the label. First, does the software handle Protected Health Information (PHI) inside a relationship covered by HIPAA? If so, the Privacy and Security Rules apply. Second, does it bill a payer such as Medicare? Then the Centers for Medicare & Medicaid Services (CMS) reimbursement rules apply. Third, does it claim to diagnose, treat, cure, or prevent disease? Then it may be a medical device under FDA authority, potentially Software as a Medical Device (SaMD). A single "digital health" product can hit none, one, or all three.
For a product team the practical move is to translate the marketing umbrella into those specific regulatory triggers, function by function, early in design. Investors and press use "digital health" loosely; regulators use it as a bucket; builders should decompose it. The common pitfall is letting the broad, comfortable label paper over a feature that quietly crosses into device territory or into PHI handling without the BAAs, consent, and safeguards those paths demand — discovering the gap during diligence or an audit rather than in design review.
